PROCEDURAL ISSUES IN HEALTH TECHNOLOGY ASSESSMENT (HTA) FOR RE-PRICING IN JAPAN

被引：0

作者：

Igarashi, A. ^{[1
]}

Aranishi, T. ^{[2
]}

Nakajima, A. ^{[3
]}

Sakai, H. ^{[4
]}

Naoi, I ^{[5
]}

Atsumi, J. ^{[6
]}

Okuyama, K. ^{[7
]}

Azuma, M. K. ^{[4
]}

Machida, M. ^{[8
]}

Yoshida, M. ^{[9
]}

Nojima, T. ^{[10
]}

Kawata, Y. ^{[11
]}

机构：

[1] Yokohama City Univ, Sch Med, Yokohama, Kanagawa, Japan

[2] Eli Lilly Japan KK, Kobe, Hyogo, Japan

[3] Teijin Pharma Ltd, Tokyo, Japan

[4] Eisai & Co Ltd, Tokyo, Japan

[5] Sumitomo Pharma Co Ltd, Chuo Ku, Osaka 13, Japan

[6] Toray Industries Ltd, Tokyo, Japan

[7] MSD KK, Tokyo, Japan

[8] Shionogi & Co Ltd, Osaka, Japan

[9] Pfizer R&D Japan GK, Tokyo, Japan

[10] Kowa Co Ltd, Tokyo, Japan

[11] Chugai Pharmaceut Co Ltd, Tokyo, Japan

来源：

VALUE IN HEALTH | 2022年 / 25卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

HTA126

引用

页码：S320 / S321

页数：2

共 50 条

[41] DISCONTINUITIES BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) AND HEALTH CARE SERVICE OBJECTIVES OF THE NHS
Brazier, P. J.
Durand, A.
Tierney, R.
Kelly, S.
VALUE IN HEALTH, 2014, 17 (07) : A450 - A450
[42] IMPACT OF CONDITIONAL MARKETING AUTHORISATION AND ACCELERATED ASSESSMENT ON HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES
Hall, D.
Tothill, A.
VALUE IN HEALTH, 2019, 22 : S797 - S797
[43] Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India
Dabak, Saudamini Vishwanath
Pilasant, Songyot
Mehndiratta, Abha
Downey, Laura Emily
Cluzeau, Francoise
Chalkidou, Kalipso
Luz, Alia Cynthia Gonzales
Youngkong, Sitaporn
Teerawattananon, Yot
HEALTH RESEARCH POLICY AND SYSTEMS, 2018, 16
[44] Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India
Saudamini Vishwanath Dabak
Songyot Pilasant
Abha Mehndiratta
Laura Emily Downey
Francoise Cluzeau
Kalipso Chalkidou
Alia Cynthia Gonzales Luz
Sitaporn Youngkong
Yot Teerawattananon
Health Research Policy and Systems, 16
[45] Does health technology assessment benefit health services and politics? The experiences of an established HTA institution: The Danish centre for evaluation and HTA
Sigmund H.
Kristensen F.B.
The European Journal of Health Economics, 2002, 3 (1) : 54 - 58
[46] Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes
Street, Jackie
Stafinski, Tania
Lopes, Edilene
Menon, Devidas
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (02) : 87 - 95
[47] SEGMENTATION OF SEVEN ASIA-PACIFIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES INTO DIFFERENT EVOLUTIONARY HTA ARCHETYPES
Mazumder, D.
Kapoor, A.
Gwatkin, N.
Medeiros, C.
VALUE IN HEALTH, 2016, 19 (07) : A832 - A832
[48] Who's afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic
Loeblova, Olga
HEALTH ECONOMICS POLICY AND LAW, 2018, 13 (02) : 137 - 161
[49] ORPHAN DRUGS: HEALTH TECHNOLOGY ASSESSMENT AND PRICING IN EUROPE
Jaroslawski, S.
Toumi, M.
Korchagina, D.
Jadot, G.
VALUE IN HEALTH, 2018, 21 : S24 - S24
[50] DIFFERENCES IN EVIDENCE REQUIREMENTS IN ONCOLOGY DRUG ASSESSMENT BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES AND EMA AND HTA BODIES AMONG THEMSELVES
Wolters, S.
Jansen, C.
Postma, M. J.
VALUE IN HEALTH, 2020, 23 : S465 - S466

← 1 2 3 4 5 →